The latest report by IMARC, titled “Malaria Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027”, finds that the global malaria diagnostics market size reached US$ 729.1 Million in 2021. Malaria diagnostics refers to the clinical assessment to detect the presence of the infection in individuals. Malaria is a life-threatening disease transmitted through the bite of an infected Anopheles mosquito that carries the plasmodium parasite. Some common symptoms include fatigue, fever, nausea, and headaches. The infection is discovered through rapid diagnostics, molecular diagnostic tests, and microscopy. Malaria diagnostics use serology techniques and antigens using indirect immunofluorescence (IFA) or enzyme-linked immunosorbent assay (ELISA). In recent years, malaria diagnostics has gained traction due to its widespread employment in laboratories, hospitals, clinics, research institutes, and diagnostic centers.
We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of the associated industries. These observations will further be integrated into the report.
Global Malaria Diagnostics Market Trends:
One of the primary factors driving the market is the rising incidences of malaria globally. Additionally, the growing awareness among individuals regarding the availability of various treatment options and diagnostics is creating a positive market outlook. Other than this, the extensive utilization of microscopic diagnostics to recognize the parasite at different stages and create suitable treatment plans is positively influencing the market growth. Besides this, numerous technological improvements, including the Quantitative Buffy Coat (QBC) method and peripheral blood smear method for detecting malaria, are creating lucrative growth opportunities for the key players. Other growth-inducing factors include the implementation of favorable government policies to promote public health and the rising healthcare expenditure capacities of the masses. Looking forward, IMARC Group expects the market value to reach US$ 1,089.5 Million by 2027, expanding at a CAGR of 7.1% during the forecast period (2022-2027).
- Based on technology, the market has been divided into microscopy, rapid diagnostic tests (RDTs), and molecular diagnostic tests (conventional PCR and real-time PCR (qPCR)).
- On the basis of the end use, the market has been segmented into hospitals, clinics, and diagnostic centers.
- Region-wise, the market has been classified into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the market has also been analyzed, with some of the key players being Abbott Laboratories, Access Bio, Beckman Coulter Inc. (Danaher Corporation), bioMerieux SA (Compagnie Merieux Alliance), Bio-Rad Laboratories Inc., Nikon Corporation, Novartis AG, Olympus Corporation, Premier Medical Corporation Pvt. Ltd., Siemens Healthcare GmbH (Siemens AG), Sysmex Corporation, and Thermo Fisher Scientific Inc.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800